January has arrived, and it's brought a whole new batch of quality movies to Prime Video. The streaming service is home to some seriously good entertainment, and this month's no different.
The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not only Eli Lilly but Novo Nordisk and Viking Therapeutics stock are suffering this morning.
NHS England has confirmed that the future of PCNs is secure for the next financial year. Speaking in a webinar for GPs on Thursday evening (9 January), NHS England said: ‘The future of PCNs is secure ...
Despite the competitive threat posed by Eli Lilly’s acquisition of Scorpion Therapeutics’ STX-478, which has shown promising efficacy in several cancer types, Relay Therapeutics’ RLY-2608 ...
In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $38.88, with a -1.09% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 0.16%.
Tune Therapeutics’ co-founders, from left: Akira Matsuno, chief financial officer; Charles Gersbach; and Fyodor Urnov, who also serves on the startup’s scientific advisory board. (Tune Photos ...
Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...
Prime Try Before You Buy will end on January 31st. Prime Try Before You Buy will end on January 31st. Wes Davis is a weekend editor who covers the latest in tech and entertainment. He has written ...
There are many ways to stream Wicked on Prime Video from a variety of devices, as well as lots of other exciting content on the platform. Here’s everything you need to know about Wicked and how to ...
Khalid bin Mohammed Al Attiyah the rank of Prime Minister. The decision was announced in the Official Gazette of the State of Qatar and is effective starting from its date of issue.
Investing.com -- Shares of Jasper Therapeutics, Inc. (Nasdaq: JSPR) plummeted over 40% following the release of data from its BEACON study of Briquilimab in Chronic Spontaneous Urticaria (CSU).